NASDAQ:PKBO Peak Bio 8/23/2024 Earnings Report Profile Peak Bio EPS ResultsActual EPS-$0.09Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APeak Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APeak Bio Announcement DetailsQuarterDate8/23/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile Peak Bio Earnings HeadlinesAkari Therapeutics announce shareholder approval connected with Peak Bio mergerNovember 9, 2024 | markets.businessinsider.comAkari Therapeutics Plc: Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. MergerNovember 8, 2024 | finanznachrichten.deGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.June 23, 2025 | Investors Alley (Ad)Peak Bio Inc (PKBO)October 20, 2024 | investing.comPeak Bio, Inc. (PKBO)September 28, 2024 | finance.yahoo.comAkari Therapeutics Plc: Rob Bazemore Appointed to the Board of Directors of Akari TherapeuticsSeptember 17, 2024 | finanznachrichten.deSee More Peak Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Peak Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Peak Bio and other key companies, straight to your email. Email Address About Peak BioPeak Bio (NASDAQ:PKBO), a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.View Peak Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Wells Fargo & Company (7/15/2025)Citigroup (7/15/2025)Charles Schwab (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
